Journal of Hepatology
Volume 47, Issue 4 , Pages 580-587 , October 2007

Which patients with genotype 1 chronic hepatitis C can benefit from prolonged treatment with the ‘accordion’ regimen?

  • Patrick Marcellin

      Affiliations

    • Service d’Hépatologie and INSERM CRB3, University Paris 7, Hôpital Beaujon, Clichy, France
    • Corresponding Author InformationCorresponding author. Address: Service d’Hepatologie, Inserm U773, 100 Bd du General Leclerc, 92110 Clichy, France. Tel.: +33 1 40875338; fax: +33 1 47309440.
    • ,
  • E. Jenny Heathcote

      Affiliations

    • University of Toronto, Toronto, Ont., Canada
    • ,
  • Antonio Craxì

      Affiliations

    • Liver & GI Unit, Di.Bi.M.I.S., University of Palermo, Italy

References 

  1. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347:975–982
  2. Hadziyannis SJ, Sette H, Morgan TR, Balan V, Diago M, Marcellin P, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med. 2004;140:346–355
  3. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001;358:958–965
  4. von Wagner M, Huber M, Berg T, Hinrichsen H, Rasenack J, Heintges T, et al. Peginterferon-alpha-2a (40kDa) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. Gastroenterology. 2005;129:522–527
  5. National Institutes of Health Consensus Development Conference Statement: Management of Hepatitis C: 2002 – June 10–12, 2002. Hepatology 2002;36:S3–S20.
  6. Dienstag JL, McHutchison JG. American gastroenterological association medical position statement on the management of hepatitis C. Gastroenterology. 2006;130:225–230
  7. Strader DB, Wright T, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C. Hepatology. 2004;39:1147–1171
  8. Zeuzem S, Fried MW, Reddy KR, Marcellin P, Diago M, Craxi A, et al. Improving the clinical relevance of pre-treatment viral load as a predictor of sustained virological response (SVR) in patients infected with hepatitis C genotype 1 treated with peginterferon alfa-2a (40kDa) (PEGASYS) plus ribavirin (COPEGUS) [abstract no. 209]. Hepatology. 2006;44:267A
  9. Ferenci P, Fried MW, Shiffman ML, Smith CI, Marinos G, Goncales FL, et al. Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin. J Hepatol. 2005;43:425–433
  10. Fried M, Jensen D, Rodriguez-Torres M, Nyberg L, Biscegli A, Morgan T, et al. Improved sustained virological response (SVR) rates with higher fixed doses of peginterferon alfa-2a (40kDa) (PEGASYS) plus ribavirin (RBV) (COPEGUS) in patients with “difficult-to-cure characteristics [abstract no. 335]. Hepatology. 2006;44:314A
  11. Davis GL, Wong JB, McHutchison JG, Manns MP, Harvey J, Albrecht J. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology. 2003;38:645–652
  12. Jensen DM, Morgan TR, Marcellin P, Pockros PJ, Reddy KR, Hadziyannis SJ, et al. Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy. Hepatology. 2006;43:954–960
  13. Zeuzem S, Buti M, Ferenci P, Sperl J, Horsmans Y, Cianciara J, et al. Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. J Hepatol. 2006;44:97–103
  14. Zeuzem S, Pawlotsky JM, Lukasiewicz E, von Wagner M, Goulis I, Lurie Y, et al. International, multicenter, randomized, controlled study comparing dynamically individualized versus standard treatment in patients with chronic hepatitis C. J Hepatol. 2005;43:250–257
  15. Drusano GL, Preston SL. A 48-week duration of therapy with pegylated interferon alpha 2b plus ribavirin may be too short to maximize long-term response among patients infected with genotype-1 hepatitis C virus. J Infect Dis. 2004;189:964–970
  16. Buti M, Valdes A, Sanchez-Avila F, Esteban R, Lurie Y. Extending combination therapy with peginterferon alfa-2b plus ribavirin for genotype 1 chronic hepatitis C late responders: a report of 9 cases. Hepatology. 2003;37:1226–1227
  17. Brouwer JT, Nevens F, Bekkering FC, Bourgeois N, Van Vlierberghe H, Weegink CJ, et al. Reduction of relapse rates by 18-month treatment in chronic hepatitis C. A Benelux randomized trial in 300 patients. J Hepatol. 2004;40:689–695
  18. Berg T, von Wagner M, Nasser S, Sarrazin C, Heintges T, Gerlach T, et al. Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. Gastroenterology. 2006;130:1086–1097
  19. Sánchez-Tapias JM, Diago M, Escartín P, Enríquez J, Romero-Gómez M, Bárcena R, et al. Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment. Gastroenterology. 2006;131:451–460
  20. Buti M, Lurie Y, Blokhina N, Teuber G, Halota W, Sumskiene J, et al. Pegylated interferon alfa-2b plus ribavirin in patients with genotype 1 chronic hepatitis C with a slow virologic response: an early enrollers analysis of the SUCCESS study [abstract no. 404]. Hepatology. 2006;44:342A
  21. Ferenci P, Laferl H, Scherzer T, Maieron A, Gschwantler M, Brunner H, et al. Customizing treatment with peginterferon alfa-2a (40kDa) (Pegasys) plus ribavirin (Copegus) in patients with HCV genotype 1 or 4 infection. Interim results of a prospective randomized trial [abstract no. 390]. Hepatology. 2006;44:336A
  22. Kaiser P, Holger H, Bissinger L, Bettina L, Sauter B, Gregor M. Extended treatment of 72 versus 48 weeks for chronic hepatitis C patients with genotype 1 and high viral load using daily consensus interferon and ribavirin [abstract no. 1128]. Hepatology. 2006;44:608A
  23. Pearlman B, Ehleben C, Saifee S. Improved virologic response rates with treatment extension to 72 weeks of peginterferon alfa-2B plus weight-based ribavirin in a difficult-to-treat population of genotype 1-infected slow responders [abstract no. 343]. Hepatology. 2006;44:318A
  24. Fuster D, Planas R, Gonzalez J, Force L, Cervantes M, Vilaro J, et al. Results of a study of prolonging treatment with pegylated interferon-alpha2a plus ribavirin in HIV/HCV-coinfected patients with no early virological response. Antivir Ther. 2006;11:473–482
  25. Nunez M, Miralles C, Berdun MA, Aguirrebengoa K, Ocampo A, Losada E. The PRESCO study: role of extended therapy and/or optimal doses of ribavirin in the treatment of chronic hepatitis C in HIV-infected patients [abstract A-2814]. In: 46th Annual interscience conference on antimicrobial agents and chemotherapy; 2006 September 27–30; San Francisco; 2006.
  26. Fontana RJ. Optimizing outcomes in hepatitis C: is treatment beyond 48 weeks ever justified?. Gastroenterology. 2006;130:1357–1362
  27. Jensen DM, Marcellin P. Rationale and design of the REPEAT study: a phase III, randomized, clinical trial of peginterferon alfa-2a (40 kDa) plus ribavirin in non-responders to peginterferon alfa-2b (12 kDa) plus ribavirin. Eur J Gastroenterol Hepatol. 2005;17:899–904
  28. Marcellin P, Freilich B, Andreone P, Brandao-Mello C, DiBisceglie A, Rai R, et al. Interim safety analysis of patients enrolled in the randomized, international REtreatment with PEGASYS in patients not responding to prior peginterferon alfa-2b/ribavirin (RBV) combination therapy (REPEAT) study. Hepatology. 2005;42:657A
  29. Marcellin P, Jensen D, Group RS. Retreatment with PEgasys® in pATients not responding to prior peginterferon alfa-2b/ribavirin (RBV) combination therapy – efficacy analysis of the 12-week induction period of the REPEAT study. Hepatology. 2005;42:749A
  30. Crone C, Gabriel GM. Comprehensive review of hepatitis C for psychiatrists: risks, screening, diagnosis, treatment, and interferon-based therapy complications. J Psychiatr Pract. 2003;9:93–110
  31. Musselman DL, Lawson DH, Gumnick JF, Manatunga AK, Penna S, Goodkin RS, et al. Paroxetine for the prevention of depression induced by high-dose interferon alfa. N Engl J Med. 2001;344:961–966
  32. Schaefer M, Schwaiger M, Garkisch AS, Pich M, Hinzpeter A, Uebelhack R, et al. Prevention of interferon-alpha associated depression in psychiatric risk patients with chronic hepatitis C. J Hepatol. 2005;42:793–798
  33. Ahern M, Imperial J, Lam S. Impact of a designated hepatology nurse on the clinical course and quality of life of patients treated with rebetron therapy for chronic hepatitis C. Gastroenterol Nurs. 2004;27:149–155
  34. Gujral H, Viscomi C, Collantes R. The role of physician extenders in managing patients with chronic hepatitis C. Cleve Clin J Med. 2004;71:S33–S37
  35. Alberti A, Clumeck N, Collins S, Gerlich W, Lundgren J, Palu G, et al. Short statement of the first European Consensus Conference on the treatment of chronic hepatitis B and C in HIV co-infected patients. J Hepatol. 2005;42:615–624
  36. Torriani FJ, Rodriguez-Torres M, Rockstroh JK, Lissen E, Gonzalez-Garcia J, Lazzarin A, et al. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med. 2004;351:438–450
  37. Nunez M, Garcia-Samaniego J, Romero M, Portu J, Barreiro P, Bonet L, et al. The PRESCO trial: impact of higher ribavirin doses and longer duration of therapy with peginterferon alfa-2a plus ribavirin in HIV-infected patients with chronic hepatitis C [abstract no. 365]. Hepatology. 2006;42:326A
  38. Pawlotsky JM. Hepatitis C: it’s a long way to new therapy, it’s a long way to go. Gastroenterology. 2004;127:1629–1632
  39. Dalgard O, Bjoro K, Hellum KB, Myrvang B, Ritland S, Skaug K, et al. Treatment with pegylated interferon and ribavarin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study. Hepatology. 2004;40:1260–1265
  40. Mangia A, Santoro R, Minerva N, Ricci GL, Carretta V, Persico M, et al. Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. N Engl J Med. 2005;352:2609–2617

☆ Prof. Patrick Marcellin declared that he is an investigator, advisor and speaker for both Roche and Schering Plough. In addition he declared he received no funding from the manufacturers or from any source to carry out this study.

PII: S0168-8278(07)00411-4

doi: 10.1016/j.jhep.2007.07.015

Journal of Hepatology
Volume 47, Issue 4 , Pages 580-587 , October 2007

Article Tools

* Image Usage & Resolution